000181400 001__ 181400
000181400 005__ 20240229145646.0
000181400 0247_ $$2doi$$a10.3389/fonc.2022.969787
000181400 0247_ $$2pmid$$apmid:35992852
000181400 0247_ $$2pmc$$apmc:PMC9386454
000181400 0247_ $$2altmetric$$aaltmetric:133644588
000181400 037__ $$aDKFZ-2022-01968
000181400 041__ $$aEnglish
000181400 082__ $$a610
000181400 1001_ $$0P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2$$aIvanova, Ekaterina$$b0$$eFirst author$$udkfz
000181400 245__ $$aCD44 expressed by myeloid cells promotes glioma invasion.
000181400 260__ $$aLausanne$$bFrontiers Media$$c2022
000181400 3367_ $$2DRIVER$$aarticle
000181400 3367_ $$2DataCite$$aOutput Types/Journal article
000181400 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661262172_31348
000181400 3367_ $$2BibTeX$$aARTICLE
000181400 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181400 3367_ $$00$$2EndNote$$aJournal Article
000181400 500__ $$aDKFZ/ZMBH Alliance /#EA: A100#LA:A100#
000181400 520__ $$aGlioblastoma multiforme (GBM) is one of the most common and malignant brain tumors in adulthood with a median survival of only 15 months. This poor prognosis is related to GBM's ability to extensively infiltrate the surrounding brain parenchyma resulting in diffuse spread of neoplastic cells in the brain, responsible for high rate of recurrence. CD44 (Cluster of Differentiation 44) is a transmembrane protein, overexpressed in multiple cancer types, including gliomas, and implicated in cell motility, proliferation and angiogenesis. Multiple studies have investigated the role of CD44 in GBM cells and have highlighted a link between tumor malignancy and CD44 expression. However up to date, little is known of the role of CD44 on cells from the tumor microenvironment (TME). Here, we have investigated a potential role of CD44 in the TME in regards to GBM invasiveness. Using an ex-vivo organotypic brain slice invasion assay, we show that absence of CD44 from the TME impairs the ability of glioma cells to invade the surrounding brain parenchyma. By deleting CD44 in the astrocytic, endothelial and myeloid compartments, we show that it is specifically CD44 expression in myeloid cells that is responsible for the observed phenotype. Combining in vivo studies in cell-specific knock-out mice and in vitro analyses on primary microglia we demonstrate that myeloid CD44 is implicated in Toll Like Receptor 2 signaling and is a major regulator of Matrix metalloproteinase 9 expression.
000181400 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000181400 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181400 650_7 $$2Other$$aCD44
000181400 650_7 $$2Other$$aMMP9
000181400 650_7 $$2Other$$aTLR2
000181400 650_7 $$2Other$$aglioblastoma
000181400 650_7 $$2Other$$amicroglia
000181400 650_7 $$2Other$$atumor microenvironment
000181400 7001_ $$0P:(DE-He78)2fe44044f40217387daaf299f2eb7340$$aCosta, Barbara$$b1$$udkfz
000181400 7001_ $$0P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e$$aEisemann, Tanja$$b2
000181400 7001_ $$0P:(DE-He78)d7efff917864e0e86459893cf0e83a99$$aLohr, Sabrina$$b3$$udkfz
000181400 7001_ $$0P:(DE-He78)843808e53ce583be326cf75564db3bdd$$aBoskovic, Pavle$$b4$$udkfz
000181400 7001_ $$0P:(DE-He78)1062e10961e437a74b9dd7542cd4ba7c$$aEichwald, Viktoria$$b5$$udkfz
000181400 7001_ $$0P:(DE-He78)cb97f86dc756543b712e4f0be836101a$$aMeckler, Jasmin$$b6
000181400 7001_ $$0P:(DE-He78)f12dec7b80065347181cf69f8233b40d$$aJugold, Manfred$$b7$$udkfz
000181400 7001_ $$aOrian-Rousseau, Veronique$$b8
000181400 7001_ $$0P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aPeterziel, Heike$$b9$$udkfz
000181400 7001_ $$0P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aAngel, Peter$$b10$$eLast author$$udkfz
000181400 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2022.969787$$gVol. 12, p. 969787$$p969787$$tFrontiers in oncology$$v12$$x2234-943X$$y2022
000181400 909CO $$ooai:inrepo02.dkfz.de:181400$$pVDB
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2fe44044f40217387daaf299f2eb7340$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d7efff917864e0e86459893cf0e83a99$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)843808e53ce583be326cf75564db3bdd$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1062e10961e437a74b9dd7542cd4ba7c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cb97f86dc756543b712e4f0be836101a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f12dec7b80065347181cf69f8233b40d$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000181400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000181400 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000181400 9141_ $$y2022
000181400 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000181400 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000181400 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000181400 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000181400 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000181400 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2021$$d2022-11-08
000181400 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000181400 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000181400 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000181400 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000181400 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:25:45Z
000181400 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000181400 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000181400 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000181400 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT ONCOL : 2021$$d2022-11-08
000181400 9202_ $$0I:(DE-He78)A100-20160331$$kA100$$lA100 Signaltransduktion/ Wachstumskontrolle$$x0
000181400 9201_ $$0I:(DE-He78)A100-20160331$$kA100$$lA100 Signaltransduktion/ Wachstumskontrolle$$x0
000181400 9201_ $$0I:(DE-He78)W240-20160331$$kW240$$lCore Facility Kleinbildgebung$$x1
000181400 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x2
000181400 9200_ $$0I:(DE-He78)A100-20160331$$kA100$$lA100 Signaltransduktion/ Wachstumskontrolle$$x0
000181400 980__ $$ajournal
000181400 980__ $$aVDB
000181400 980__ $$aI:(DE-He78)A100-20160331
000181400 980__ $$aI:(DE-He78)W240-20160331
000181400 980__ $$aI:(DE-He78)B310-20160331
000181400 980__ $$aUNRESTRICTED